Literature DB >> 1271240

Ergot alkaloids: hepatic distribution and estimation of absorption by measurement of total radioactivity in bile and urine.

F Nimmerfall, J Rosenthaler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 1271240     DOI： 10.1007/BF01271444

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN： 0090-466X


× No keyword cloud information.
  12 in total

1.  Permanent bile duct cannulation in the monkey. A model for studying intestinal absorption.

Authors:  J Meszaros; F Nimmerfall; J Rosenthaler; H Weber
Journal:  Eur J Pharmacol       Date:  1975 Jun-Jul       Impact factor: 4.432

2.  THE METABOLITES OF ERGOMETRINE AND LYSERGIC ACID DIETHYLAMIDE IN RAT BILE.

Authors:  M B SLAYTOR; S E WRIGHT
Journal:  J Med Pharm Chem       Date:  1962-05

3.  Route of administration and drug metabolism.

Authors:  M Gibaldi; S Feldman
Journal:  Eur J Pharmacol       Date:  1972-09       Impact factor: 4.432

4.  Effect of route of administration on drug disposition.

Authors:  S Riegelman; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1973-10

5.  Influence of route of administration on drug availability.

Authors:  M Rowland
Journal:  J Pharm Sci       Date:  1972-01       Impact factor: 3.534

6.  Pharmacokinetic basis for the influence of route of administration on the area under the plasma concentration-time curve.

Authors:  M Gibaldi; S Feldman
Journal:  J Pharm Sci       Date:  1969-12       Impact factor: 3.534

Review 7.  The biliary excretion and enterohepatic circulation of drugs and other organic compounds.

Authors:  R L Smith
Journal:  Fortschr Arzneimittelforsch       Date:  1966

8.  Influence of the route of administration on the area under the plasma concentration-time curve.

Authors:  P A Harris; S Riegelman
Journal:  J Pharm Sci       Date:  1969-01       Impact factor: 3.534

9.  [Methodical problems in clinical-pharmacological research].

Authors:  H J Dengler
Journal:  Arzneimittelforschung       Date:  1971-10

10.  Influence of first-pass effect on availability of drugs on oral administration.

Authors:  M Gibaldi; R N Boyes; S Feldman
Journal:  J Pharm Sci       Date:  1971-09       Impact factor: 3.534
View more
  10 in total

1.  Investigation of the venoconstrictor effect of 8' hydroxydihydroergotamine, the main metabolite of dihydroergotamine, in man.

Authors:  W H Aellig
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

2.  Quantitative determination of ergot alkaloids in biological fluids by radioimmunoassay.

Authors:  T T Kleimola
Journal:  Br J Clin Pharmacol       Date:  1978-09       Impact factor: 4.335

3.  Ergovaline movement across Caco-2 cells.

Authors:  Nancy W Shappell; David J Smith
Journal:  In Vitro Cell Dev Biol Anim       Date:  2005 Sep-Oct       Impact factor: 2.416

Review 4.  Co-dergocrine mesylate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in age-related cognitive decline.

Authors:  A N Wadworth; P Chrisp
Journal:  Drugs Aging       Date:  1992 May-Jun       Impact factor: 3.923

Review 5.  Clinical pharmacokinetics of ergotamine in migraine and cluster headache.

Authors:  V L Perrin
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

6.  Elucidation of the structure and receptor binding studies of the major primary, metabolite of dihydroergotamine in man.

Authors:  G Maurer; W Frick
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

7.  Ergotamine absorption and toxicity.

Authors:  D A Orton; R J Richardson
Journal:  Postgrad Med J       Date:  1982-01       Impact factor: 2.401

8.  Fate and disposition of bromocriptine in animals and man. II: Absorption, elimination and metabolism.

Authors:  G Maurer; E Schreier; S Delaborde; R Nufer; A P Shukla
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1983       Impact factor: 2.441

9.  Ergotamine abuse and extra-hepatic portal hypertension.

Authors:  P E Fisher; D B Silk; N Menzies-Gow; M Dingle
Journal:  Postgrad Med J       Date:  1985-05       Impact factor: 2.401

10.  Ergovaline toxicity on Caco-2 cells as assessed by MTT, alamarBlue, and DNA assays.

Authors:  Nancy W Shappell
Journal:  In Vitro Cell Dev Biol Anim       Date:  2003 Jul-Aug       Impact factor: 2.416
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.